How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree with the proposal not to update the guideline? Please provide reasons for your answer.

  • Question on Consultation

    Do you agree with the proposal to monitor the areas outlined in the surveillance proposal? Please provide reasons for your answer.

  • Question on Consultation

    Are you aware of important evidence relevant to CG155 that we have not considered in the Evidence summary? (If yes please provide details)

  • Question on Consultation

    Do you have any comments on equalities issues?
The content on this page is not current guidance and is only for the purposes of the consultation process.

2021 surveillance of psychosis and schizophrenia in children and young people: recognition and management

Closed for comments This consultation ended on at   Request commenting lead permission

Surveillance proposal

We will not update the guideline on psychosis and schizophrenia in children and young people. We will monitor the evidence base for new evidence in the following areas and assess its impact as it publishes:

  • The effectiveness of antipsychotics for preventing transition to full psychosis in children and young people with psychotic symptoms or mental state changes insufficient for a diagnosis of psychosis or schizophrenia.

  • Lurasidone for treating first episode and subsequent acute episodes of schizophrenia.

  • The benefit of adding cognitive behavioural therapy (CBT) to standard care including antipsychotics.

  • Weight management interventions for children, young people and adults receiving antipsychotics for psychosis and schizophrenia and bipolar disorder; and for children and young people receiving them for antisocial behaviour and conduct disorders.

Reasons for the proposal

The evidence we identified is either equivocal, supports recommendations, or is not considered enough on its own to change them. We identified new evidence that indicated practice in some areas was developing rapidly and we propose actively monitoring those areas for new evidence that may impact recommendations.

For further details and a summary of all evidence identified in surveillance, see the summary of evidence from surveillance.